John Wilkerson from STAT News - Journalist Profile

	Profile	Recent Articles on Subject
1	John Wilkerson STAT News STAT Washington correspondent. Healthcare Journalism	STAT+: Congressional probe questions clinical trials run in China, citing Army involvement - 18 days ago STAT+: House hearing keeps pressure on PBM practices while Congress considers reforms - about 2 months ago STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 2 months ago How U.S. responses to public health emergencies could be hamstrung by the Supreme Court - 2 months ago Supreme Court undercuts regulators’ authority across government - 2 months ago NIH wanted to make cancer research more diverse. The effort turned out to be a costly failure - 3 months ago STAT+: Senate drug shortage bill would pay hospitals bonuses for good contracting practices - 4 months ago STAT+: Boehringer Ingelheim layoffs are a sign of dysfunctional Humira biosimilar market - 5 months ago STAT+: The White House has a plan to stem drug shortages - 5 months ago STAT+: Here’s what you might have missed in Biden’s budget proposal - 6 months ago In his State of the Union, Biden takes clear aim at ‘Big Pharma’ - 6 months ago STAT+: What does America’s crackdown on Chinese firms mean for the U.S. biotech sector? - 6 months ago STAT+: Congress punts on PBM reform efforts - 6 months ago STAT+: Key Senate panel considers Medicare bonuses for hospitals that prevent drug shortages - 8 months ago Biden’s FDA is letting Ron DeSantis import cheaper drugs from Canada. Who gets to take credit? - 8 months ago STAT+: 3 FDA staffers to watch in 2024 - 9 months ago STAT+: Venture capital is still pouring into drug research despite Medicare price negotiation - 9 months ago STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year? - 9 months ago STAT+: Sanders blames food companies for diabetes epidemic - 9 months ago STAT+: Senate panel considers Medicare policy fixes to drug shortages - 9 months ago STAT+: Cancer drug shortages won’t get better under Biden’s latest plan - 9 months ago STAT+: Biden defends Trump-era drug pricing rule on copay accumulators - 9 months ago STAT+: FDA chief scientist to replace Woodcock - 9 months ago STAT+: Biden invokes Defense Production Act to stem drug shortages - 9 months ago STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs - 9 months ago STAT+: Prominent pharmaceutical industry ally Anna Eshoo to retire - 10 months ago STAT+: Delay of eye drop recall highlights FDA’s impotence on the issue - 10 months ago STAT+: FDA’s Janet Woodcock to retire early next year - 10 months ago STAT+: House panel passes PBM reforms, ratcheting up chance for passage - 10 months ago STAT+: To get things done fast at FDA: ‘Don’t tell anybody,’ cancer chief says - 10 months ago STAT+: FDA’s Califf wants to get the public as excited about life expectancy as cures - 10 months ago Senate committee plans Nov. 8 vote on wide-ranging health care package - 11 months ago STAT+: ALS patients support bill that could help patients with other rare diseases - 11 months ago STAT+: Europe takes steps to head off drug shortages, even as U.S. proposals stall - 11 months ago STAT+: Pharmacists can make shortage drugs, but at what cost? - 11 months ago STAT+: House committee hearing kicks off potential doctor pay reforms in Medicare - 11 months ago STAT+: Actually, hospital price transparency does save money, advocate highlights - 11 months ago STAT+: Senate Finance targets Medicare Advantage brokers - 11 months ago STAT+: When Medicare paid doctors differently, fewer patients had heart problems - 11 months ago STAT+: 3 questions for the future of Biden’s cancer moonshot - 11 months ago STAT+: Hearing on Medicare drug price negotiation gets unusually heated - 12 months ago STAT+: PBMs were the target of House hearing, but pharma wasn’t spared criticism - 12 months ago
2	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 2 months ago
3	Lizzy Lawrence STAT News Medical devices reporter at STATnews. Loves news tips. medical reportingnews	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 2 months ago
4	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry - 2 months ago
5	Sarah Owermohle STAT News Health reporter @STATNews. Covers Biden's agenda. Washington, District of Columbia health policyjournalism	Supreme Court undercuts regulators’ authority across government - 2 months ago STAT+: Here’s what you might have missed in Biden’s budget proposal - 6 months ago
6	Bob Herman STAT News Health care business reporter. Indiana Health carebusiness	Supreme Court undercuts regulators’ authority across government - 2 months ago
7	Rachel Cohrs STAT News Washington Correspondent @statnews. Washington, DC health policyjournalism	STAT+: Congress punts on PBM reform efforts - 6 months ago STAT+: Prominent pharmaceutical industry ally Anna Eshoo to retire - 10 months ago Senate committee plans Nov. 8 vote on wide-ranging health care package - 11 months ago
8	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: A growing number of U.S. states, cities, and counties are suing insulin makers and PBMs - 9 months ago STAT+: FDA’s Janet Woodcock to retire early next year - 10 months ago